6
项与 重组诺如病毒双价(GI.1/GII.4)疫苗(汉逊酵母)(国药中生生物技术研究院有限公司) 相关的临床试验A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha) in Healthy People Aged 6 Months to 13 Years
The purpose of this study is to evaluate the Efficacy, Safety and Immunogenicity of the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha) in Healthy People Aged 6 Months to 13 Years After Vaccination
Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine(Hansenula Polymorpha) in Healthy People Aged Aged From 6 Months to 59 Years
Phase II clinical study will explore dose and safety, immunogenicity in 4 age groups, including 18-59 years old group, 6-17 years old group, 3-5 years old group, 6-35 months old group, with a total of 1716 subjects.
/ Active, not recruiting临床2期 评价重组诺如病毒双价(GI.1/GII.4)疫苗(汉逊酵母)接种于6月龄~59岁健康人群免疫原性和安全性的随机、双盲、安慰剂对照Ⅱ期临床试验
评价6月龄~59岁健康人群接种不同剂量重组诺如病毒双价(GI.1/GII.4)疫苗(汉逊酵母)全程免疫后14天的免疫原性。进一步评价在6月龄~59岁健康人群接种不同剂量试验疫苗的安全性;探索试验疫苗在6月龄~59岁健康人群中的免疫持久性。
100 项与 重组诺如病毒双价(GI.1/GII.4)疫苗(汉逊酵母)(国药中生生物技术研究院有限公司) 相关的临床结果
100 项与 重组诺如病毒双价(GI.1/GII.4)疫苗(汉逊酵母)(国药中生生物技术研究院有限公司) 相关的转化医学
100 项与 重组诺如病毒双价(GI.1/GII.4)疫苗(汉逊酵母)(国药中生生物技术研究院有限公司) 相关的专利(医药)
100 项与 重组诺如病毒双价(GI.1/GII.4)疫苗(汉逊酵母)(国药中生生物技术研究院有限公司) 相关的药物交易